Full-Time
Mechanical Engineer
Fluidics/Perfusion
UntilLabs
51-200 employees
Advances reversible organ cryopreservation technology
Compensation Overview
$120k - $200k/yr
California, USA
In Person
 Mechanical Engineering (1) |
|---|
Get referred to UntilLabs
See people who can refer or advise you
- Track record of exceptional engineering abilities
- Deep understanding of heat and mass transfer principles
- Experience designing fluidic systems for perfusion/heat exchangers
- High degree of autonomy across full engineering stack: electromechanical design and fabrication, control software, physical modeling
- Desire to join a fast-paced, scrappy engineering team
- Develop perfusion systems, cryoprotectant formulations, and vitrification and rewarming hardware as part of an interdisciplinary team
- Contribute to hardware design, modeling, and testing across the full engineering stack to advance cryopreservation technology
- Collaborate with cross-disciplinary teams to achieve organ-scale reversible cryopreservation goals
- Engage in hands-on fabrication and integration of electromechanical components and control software as needed
- 3+ years experience or graduate level in Mechanical Engineering, Physics, or equivalent
- Experience with organ perfusion in a research or clinical context
- Experience working in a startup
UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2024
Get referred to UntilLabs
See people who can refer or advise you
Simplify's Take
What believers are saying
- Until Labs raised $58M on 2025-09-22 from Founders Fund, Lux, and Field Ventures.
- Its 2026 careers page shows aggressive hiring across biology, engineering, legal, and operations.
- The roadmap targets kidney, liver, heart validation and GLP studies for first-in-human trials.
What critics are saying
- Organ cryopreservation remains scientifically unproven for human transplantation by 2026.
- The 2025-09-22 Series A still funds research, not clinical product revenue.
- Failure in large-animal organs before 2027 kills its transplant and hibernation thesis.
What makes UntilLabs unique
- Until Labs combines organ perfusion, cryoprotectants, cooling, and rewarming hardware.
- Its organ-scale focus directly targets transplant logistics, not distant whole-body speculation.
- The 2026 alternating magnetic-field rewarming blog shows real engineering depth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Commuter Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 22%Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.
Fenwick represents Until Labs in $58M Series A funding.